CA3086842A1 - Il-2 variant - Google Patents
Il-2 variant Download PDFInfo
- Publication number
- CA3086842A1 CA3086842A1 CA3086842A CA3086842A CA3086842A1 CA 3086842 A1 CA3086842 A1 CA 3086842A1 CA 3086842 A CA3086842 A CA 3086842A CA 3086842 A CA3086842 A CA 3086842A CA 3086842 A1 CA3086842 A1 CA 3086842A1
- Authority
- CA
- Canada
- Prior art keywords
- amino acid
- formula
- residue
- chem
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017-252224 | 2017-12-27 | ||
| JP2017252224 | 2017-12-27 | ||
| PCT/JP2018/048361 WO2019131964A1 (ja) | 2017-12-27 | 2018-12-27 | Il-2改変体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3086842A1 true CA3086842A1 (en) | 2019-07-04 |
Family
ID=67067530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3086842A Pending CA3086842A1 (en) | 2017-12-27 | 2018-12-27 | Il-2 variant |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12280118B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3733693A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7275049B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102740971B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN111868079B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018394189B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3086842A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW201930345A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019131964A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114514241A (zh) * | 2019-08-15 | 2022-05-17 | 赛缇姆治疗公司 | 经修饰的白细胞介素2(il-2)多肽、缀合物以及其用途 |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
| AU2018273914A1 (en) | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| IL321812A (en) | 2017-08-03 | 2025-08-01 | Synthorx Inc | Cytokine complexes for the treatment of autoimmune diseases |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US12565525B2 (en) | 2018-03-28 | 2026-03-03 | Ascendis Pharma Oncology Division A/S | IL-2 conjugates |
| AU2019301697A1 (en) * | 2018-07-13 | 2021-01-07 | Il-2Rx, Inc. | Compounds, compositions, methods, and uses for treating cancer and immunological disorders |
| CA3098930A1 (en) | 2018-09-21 | 2020-03-26 | Innovent Biologics (Suzhou) Co., Ltd. | Novel interleukin-2 and use thereof |
| TW202031284A (zh) | 2018-11-08 | 2020-09-01 | 美商新索思股份有限公司 | 介白素10結合物及其用途 |
| MA54952A (fr) | 2019-02-06 | 2022-05-11 | Synthorx Inc | Conjugués d'il-2 et méthodes d'utilisation de ceux-ci |
| AU2020279240A1 (en) | 2019-05-20 | 2021-12-23 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
| CA3148135A1 (en) | 2019-08-23 | 2021-03-04 | Carolina E. CAFFARO | Il-15 conjugates and uses thereof |
| WO2021050554A1 (en) | 2019-09-10 | 2021-03-18 | Synthorx, Inc. | Il-2 conjugates and methods of use to treat autoimmune diseases |
| CN114437198A (zh) * | 2019-12-17 | 2022-05-06 | 北京志道生物科技有限公司 | 白介素-2衍生物 |
| WO2021143572A1 (zh) * | 2020-01-15 | 2021-07-22 | 天津键凯科技有限公司 | 一种制备结合位点可控的peg化生物分子的方法 |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| KR102986821B1 (ko) * | 2020-04-22 | 2026-07-06 | 머크 샤프 앤드 돔 엘엘씨 | 인터류킨-2 수용체 베타 감마c 이량체에 대해 편향되고 비펩티드성 수용성 중합체에 접합된 인간 인터류킨-2 접합체 |
| CA3178074A1 (en) | 2020-06-03 | 2021-12-09 | Nina Gunnarsson | Il-2 sequences and uses thereof |
| WO2022081728A2 (en) * | 2020-10-14 | 2022-04-21 | Cytimm Therapeutics, Inc. | Modified interleukin 2 (il-2) polypeptides, and methods of making and using the same |
| CN113698468B (zh) * | 2021-09-01 | 2022-10-11 | 浙江新码生物医药有限公司 | 人白细胞介素2-聚乙二醇偶联物及其应用 |
| JP7864826B2 (ja) * | 2021-09-22 | 2026-05-25 | フォートビタ バイオロジクス(シンガポール)プライベート リミティド | インターロイキン2変異体およびその融合タンパク質 |
| CN116769013A (zh) * | 2022-03-10 | 2023-09-19 | 广东菲鹏制药股份有限公司 | 白细胞介素2突变体以及含有其的复合物 |
| CN115850436B (zh) * | 2022-10-14 | 2026-02-03 | 海徕科(北京)生物技术有限公司 | 白介素2突变体及其应用 |
| WO2024118780A2 (en) * | 2022-11-30 | 2024-06-06 | Binacea Pharma, Inc. | Il-2 mutants and uses thereof |
| EP4741410A1 (en) * | 2023-07-06 | 2026-05-13 | Glytech, Inc. | Solubilization group for poorly water-soluble proteins |
| IL330442A (en) * | 2024-01-08 | 2026-08-01 | Fbd Biologics Ltd | Engineered variants of IL-2 and methods for using them |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1388836A (en) | 1971-06-01 | 1975-03-26 | Medisan Ab | Cosmetic compositions |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| EP0229108B1 (en) * | 1985-06-26 | 1990-12-27 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5417970A (en) | 1988-10-21 | 1995-05-23 | Sanofi | Drugs containing a glycosylated interleukin-2 |
| US4902502A (en) * | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US5153310A (en) * | 1989-02-28 | 1992-10-06 | Du Pont Merck Pharmaceutical Company | Il-2 analogs containing n-linked glycosylation sites |
| US5312903A (en) | 1990-06-01 | 1994-05-17 | E. I. Du Pont De Nemours And Company | Lysine-glycosylated recombinant interleukin-2 |
| ATE375363T1 (de) * | 1997-07-14 | 2007-10-15 | Bolder Biotechnology Inc | Derivate des wachstumshormons und verwandte proteine |
| US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| US7070959B1 (en) * | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| KR100775805B1 (ko) | 2001-06-19 | 2007-11-12 | 오츠카 가가쿠 가부시키가이샤 | 당쇄 아스파라긴 유도체의 제조 방법 |
| EP1421187B1 (en) | 2001-07-27 | 2007-10-10 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Systems for in vivo site-directed mutagenesis using oligonucleotides |
| EP1454138B1 (en) | 2001-12-04 | 2012-01-18 | Merck Patent GmbH | Immunocytokines with modulated selectivity |
| US7943763B2 (en) | 2002-07-05 | 2011-05-17 | Otsuka Chemical Holdings Co., Ltd. | Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides |
| JP5087274B2 (ja) * | 2003-06-30 | 2012-12-05 | ドマンティス リミテッド | ポリペプチド |
| WO2005007121A2 (en) * | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
| KR100731875B1 (ko) | 2003-07-28 | 2007-06-25 | 오츠카 가가쿠 가부시키가이샤 | 아미노화 복합형 당사슬 유도체 및 그의 제조방법 |
| CN1930300A (zh) * | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
| DE102008023820A1 (de) | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
| WO2010085495A1 (en) | 2009-01-21 | 2010-07-29 | Amgen Inc. | Compositions and methods of treating inflammatory and autoimmune diseases |
| ES2866674T3 (es) | 2010-11-12 | 2021-10-19 | Nektar Therapeutics | Conjugados de una fracción de IL-2 y un polímero |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| US9738724B2 (en) | 2012-06-08 | 2017-08-22 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| WO2014028748A1 (en) | 2012-08-15 | 2014-02-20 | Irm Llc | Interleukin 2 antibodies and antibody complexes |
| US9670521B2 (en) | 2012-09-24 | 2017-06-06 | Medimmune Limited | Amino acid derivatives |
| WO2014124258A2 (en) | 2013-02-08 | 2014-08-14 | Irm Llc | Specific sites for modifying antibodies to make immunoconjugates |
| US9580486B2 (en) | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| WO2015109212A1 (en) | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anti-il-2 antibodies and compositions and uses thereof |
| KR102493543B1 (ko) | 2014-07-21 | 2023-01-30 | 데리니아, 인크. | 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자 |
| JP6640834B2 (ja) | 2014-08-11 | 2020-02-05 | デリニア, インコーポレイテッド | 自己免疫疾患の処置のために調節性t細胞を選択的に活性化させる改変il−2変異体 |
| IL304950A (en) * | 2015-04-10 | 2023-10-01 | Amgen Inc | Interleukin for the expansion of myotonic control T-2 cells |
| JP6967221B2 (ja) | 2015-08-19 | 2021-11-17 | 国立研究開発法人理化学研究所 | 非天然アミノ酸導入抗体 |
-
2018
- 2018-12-27 CN CN201880083560.4A patent/CN111868079B/zh active Active
- 2018-12-27 CA CA3086842A patent/CA3086842A1/en active Pending
- 2018-12-27 KR KR1020207018206A patent/KR102740971B1/ko active Active
- 2018-12-27 US US16/958,045 patent/US12280118B2/en active Active
- 2018-12-27 EP EP18897857.1A patent/EP3733693A4/en not_active Withdrawn
- 2018-12-27 JP JP2019562482A patent/JP7275049B2/ja active Active
- 2018-12-27 TW TW107147546A patent/TW201930345A/zh unknown
- 2018-12-27 WO PCT/JP2018/048361 patent/WO2019131964A1/ja not_active Ceased
- 2018-12-27 AU AU2018394189A patent/AU2018394189B2/en active Active
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114514241A (zh) * | 2019-08-15 | 2022-05-17 | 赛缇姆治疗公司 | 经修饰的白细胞介素2(il-2)多肽、缀合物以及其用途 |
| EP4013777A4 (en) * | 2019-08-15 | 2024-01-17 | Cytimm Therapeutics, Inc. | MODIFIED INTERLEUKIN 2 (IL-2) POLYPEPTIDES, CONJUGATES AND USES THEREOF |
| CN114514241B (zh) * | 2019-08-15 | 2026-03-24 | 赛缇姆治疗公司 | 经修饰的白细胞介素2(il-2)多肽、缀合物以及其用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2019131964A1 (ja) | 2020-12-10 |
| KR20200103681A (ko) | 2020-09-02 |
| KR102740971B1 (ko) | 2024-12-11 |
| TW201930345A (zh) | 2019-08-01 |
| US12280118B2 (en) | 2025-04-22 |
| WO2019131964A1 (ja) | 2019-07-04 |
| AU2018394189A1 (en) | 2020-07-16 |
| CN111868079B (zh) | 2025-06-17 |
| AU2018394189B2 (en) | 2023-12-21 |
| EP3733693A4 (en) | 2021-12-22 |
| CN111868079A (zh) | 2020-10-30 |
| EP3733693A1 (en) | 2020-11-04 |
| US20210060169A1 (en) | 2021-03-04 |
| JP7275049B2 (ja) | 2023-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7275049B2 (ja) | Il-2改変体 | |
| ES2807260T3 (es) | Variantes de IL-2 modificadas que activan selectivamente las células T reguladoras para el tratamiento de enfermedades autoinmunes | |
| CN106795213B (zh) | 选择性地活化调节性t细胞用于治疗自身免疫病的分子 | |
| ES2565834T3 (es) | Agentes de unión a receptor de Fc de región constante de inmunoglobulina | |
| ES2651170T3 (es) | Moléculas de fusión solubles multímeras de IL-15 y métodos para elaborar y usar las mismas | |
| US20220064609A1 (en) | Expression of novel cell tags | |
| JP2019507589A (ja) | 自己免疫疾患の治療のために制御性t細胞を選択的に活性化する分子 | |
| EA024877B1 (ru) | Связывающие множество мишеней белки, обладающие антагонистическими свойствами по отношению к cd86 | |
| US10316087B2 (en) | Soluble and stable heterodimeric TCR | |
| WO2020132365A2 (en) | T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof | |
| WO2020132366A2 (en) | T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof | |
| JP2025508824A (ja) | 活性化可能なil-18ポリペプチド | |
| JP2026053539A (ja) | Icd statシグナル伝達が改変されたcd122 | |
| Qian et al. | Long-acting human interleukin 2 bioconjugate modified with fatty acids by sortase A | |
| JP6415716B2 (ja) | 可溶性のヘテロ二量体t細胞受容体およびその製法と使用 | |
| HK40038441A (en) | Il-2 variant | |
| EP4454710A1 (en) | Bispecific fusion proteins with immunosuppressive activity | |
| WO2023005859A1 (zh) | 针对抗原ssx2的高亲和力t细胞受体 | |
| HK1261663A1 (en) | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231130 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250513 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250911 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251104 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251104 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260112 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260112 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260112 |